Ligand Pharmaceuticals (NASDAQ:LGND) Given New $262.00 Price Target at Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised its price target on Ligand to $262 (from $252) and kept an "outperform" rating — analyst consensus is a "Moderate Buy" with an average target around $257.71 after several recent target increases.
• Ligand missed Q1 estimates (EPS $1.63 vs. $1.84 expected; revenue $51.7M vs. $59.1M) but showed 14.1% year-over-year revenue growth, strong margins, a 56% increase in royalty revenue, and management reaffirmed 2026 guidance with a partial contribution expected from the pending XOMA acquisition.
• Insiders have sold recently — 35,448 shares worth $7.45M over the past 90 days — although insiders still own about 7% of the company and institutional investors hold roughly 91%.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) had its target price increased by Royal Bank Of Canada from $252.00 to $262.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an "outperform" rating on the biotechnology company's stock. Royal Bank Of Canada's price objective suggests a potential upside of 18.40% from the stock's current price.

Several other analysts have also commented on the company. HC Wainwright raised their target price on Ligand Pharmaceuticals from $243.00 to $289.00 and gave the stock a "buy" rating in a report on Thursday, April 30th. Wall Street Zen lowered Ligand Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. Oppenheimer raised their target price on Ligand Pharmaceuticals from $275.00 to $277.00 and gave the stock an "outperform" rating in a report on Friday, February 27th. Weiss Ratings raised Ligand Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, May 1st. Finally, Citigroup raised their target price on Ligand Pharmaceuticals from $276.00 to $282.00 and gave the stock a "buy" rating in a report on Wednesday, April 15th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Ligand Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $257.71.

Ligand Pharmaceuticals Stock Performance

Shares of LGND stock traded up $10.95 during mid-day trading on Friday, reaching $221.28. The stock had a trading volume of 81,943 shares, compared to its average volume of 225,877. The business's fifty day moving average is $212.17 and its 200-day moving average is $200.56. The company has a current ratio of 22.23, a quick ratio of 21.98 and a debt-to-equity ratio of 0.44. The firm has a market cap of $4.43 billion, a price-to-earnings ratio of 37.95, a PEG ratio of 1.89 and a beta of 1.20. Ligand Pharmaceuticals has a 1-year low of $98.89 and a 1-year high of $247.38.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) last posted its earnings results on Thursday, May 14th. The biotechnology company reported $1.63 EPS for the quarter, missing the consensus estimate of $1.84 by ($0.21). The company had revenue of $51.72 million for the quarter, compared to analyst estimates of $59.10 million. Ligand Pharmaceuticals had a return on equity of 13.86% and a net margin of 46.42%.The firm's revenue was up 14.1% on a year-over-year basis. During the same period last year, the business earned $1.33 earnings per share. On average, research analysts forecast that Ligand Pharmaceuticals will post 5.46 earnings per share for the current year.

Insiders Place Their Bets

In other Ligand Pharmaceuticals news, Director Stephen L. Sabba sold 2,034 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $201.50, for a total transaction of $409,851.00. Following the transaction, the director owned 33,793 shares in the company, valued at approximately $6,809,289.50. This represents a 5.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John W. Kozarich sold 467 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $202.23, for a total value of $94,441.41. Following the transaction, the director owned 42,253 shares in the company, valued at $8,544,824.19. This represents a 1.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 35,448 shares of company stock worth $7,450,977. Company insiders own 7.00% of the company's stock.

Hedge Funds Weigh In On Ligand Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC lifted its position in shares of Ligand Pharmaceuticals by 2.9% in the third quarter. Ashton Thomas Private Wealth LLC now owns 2,014 shares of the biotechnology company's stock valued at $357,000 after acquiring an additional 56 shares in the last quarter. Maryland State Retirement & Pension System lifted its position in shares of Ligand Pharmaceuticals by 2.2% in the fourth quarter. Maryland State Retirement & Pension System now owns 2,872 shares of the biotechnology company's stock valued at $543,000 after acquiring an additional 61 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Ligand Pharmaceuticals by 31.6% in the third quarter. Smartleaf Asset Management LLC now owns 271 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 65 shares in the last quarter. CIBC Private Wealth Group LLC lifted its position in shares of Ligand Pharmaceuticals by 86.3% in the third quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company's stock valued at $26,000 after acquiring an additional 69 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Ligand Pharmaceuticals by 3.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 2,688 shares of the biotechnology company's stock valued at $527,000 after acquiring an additional 78 shares in the last quarter. Hedge funds and other institutional investors own 91.28% of the company's stock.

Ligand Pharmaceuticals News Summary

Here are the key news stories impacting Ligand Pharmaceuticals this week:

• Positive Sentiment: Company-released results highlight a 56% year-over-year increase in royalty revenue and management reaffirmed its recently raised 2026 guidance while noting an expected partial-year contribution from the pending XOMA royalty acquisition — a driver of recurring revenue and guidance stability. Ligand Reports First Quarter 2026 Financial Results
• Positive Sentiment: HC Wainwright reiterated a Buy stance and published bullish multi-year EPS forecasts (FY2026 ~ $6.08–$6.12; FY2027 ~$8.52) with a $289 price target — analyst optimism can support further upside and investor confidence. HC Wainwright estimates / MarketBeat
• Positive Sentiment: Ligand made a strategic $15M investment in Orchestra BioMed under a previously announced arrangement — this supports partnership pipeline opportunities and potential royalty or milestone upside over time. Orchestra BioMed Receives $15 Million Investment from Ligand
• Neutral Sentiment: Company materials (press release, slide deck, conference call) are available for investors — useful for details on segment performance, guidance assumptions, and XOMA acquisition timing but not immediate price catalysts. Q1 2026 Press Release / Slide Deck
• Negative Sentiment: Q1 results missed consensus: EPS $1.63 vs. $1.84 expected and revenue $51.7M vs. $59.1M expected — the top-line and EPS miss is a near-term negative; however, margins remain strong and revenue grew year-over-year 14.1%, partially muting the impact. Ligand: Q1 Earnings Snapshot

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company's product offerings center around several core platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.